ESR1 and cancer: Tamoxifen, used in the treatment of ER/PgR‐positive cancers, is reduced by the CYP enzymes into its active metabolites N‐desmethyl‐tamoxifen, 4‐hydroxyl‐N‐desmethyl‐tamoxifen, and 4‐hydroxy‐tamoxifen [59].